Treatment of gout and hyperuricemia

Abstract

Sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate is described. In addition, pharmaceutical compositions and uses of such compositions for the treatment of a variety of diseases and conditions are described.

1 . A method of reducing serum uric acid levels, treating hyperuricemia, or treating gout in a human comprising co-administration of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate, or a pharmaceutically acceptable salt thereof, and febuxostat to the human, wherein said method provides
 serum urate levels of less than 6 mg/dL; and   wherein said method provides a serum urate levels intraday change from baseline of more than 50%.   
     
     
         2 . A method of reducing serum uric acid levels, treating hyperuricemia, or treating gout in a human comprising co-administration of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate, or a pharmaceutically acceptable salt thereof, and febuxostat to the human, wherein said method provides
 serum urate levels of less than 4 mg/dL.   
     
     
         3 . (canceled) 
     
     
         4 . (canceled) 
     
     
         5 . (canceled) 
     
     
         6 . A method of treating gout in a human comprising co-administration of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate, or a pharmaceutically acceptable salt thereof, and febuxostat to the human, wherein said method provides serum urate levels of less than 6 mg/dL; and wherein the gout in the human is characterized by the presence of large accumulated deposits of uric acid or tophi. 
     
     
         7 .- 25 . (canceled) 
     
     
         26 . A method of reducing serum uric acid levels, treating hyperuricemia, or treating gout in a human comprising co-administration of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate, or a pharmaceutically acceptable salt thereof, and febuxostat to the human, wherein the method provides serum urate levels of less than 6 mg/dL, and wherein said method results in an adverse event in less than 15% of the subjects.